On the role of the peroxisome in cell differentiation and carcinogenesis

Molecular and Cellular Biochemistry

Volumn 187, Issue 1-2, 1998, Pages 85-97

  Masters, Colin ^a   Crane, Denis ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Carcinogenesis; Differentiation; Peroxisome

Indexed keywords

CARCINOGEN; OMEGA 3 FATTY ACID; OXYGEN RADICAL; PEROXISOME PROLIFERATOR; RETINOID; STEROID HORMONE;

APOPTOSIS; CARCINOGENESIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL ORGANELLE; GENOTOXICITY; PEROXISOME; REVIEW;

ANIMALS; CARCINOGENS; CATALASE; CELL DIFFERENTIATION; CELL DIVISION; GROWTH SUBSTANCES; HUMANS; MICROBODIES; NEOPLASMS; OXIDATIVE STRESS; PEROXISOME PROLIFERATORS; SIGNAL TRANSDUCTION;

EID: 0031687071     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006863123068     Document Type: Review

References (71)

1. Harris CC: Chemical and physical carcinogenesis: Advances and perspectives for the 1990's. Cancer Res 51 (Suppl): 5023S-5044S,1991
2. Ames BN, Gold LS, Willett WC: The causes and prevention of cancer. Proc Natl Acad Sci 92: 5258-5265,1995
3. Masters CJ, Holmes RS: Haemoglobin, isoenzymes and tissue differentiation, North Holland. Frontiers of Biology Series, Amsterdam,1975
4. Reddy JK, Azamoff DL, Highnite CE: Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283: 397-398,1980
5. Masters CJ, Crane DI: On the role of the peroxisome in ontogeny, ageing and degenerative disease. Mech Ageing Devel 80: 69-83,1995
6. Lake BG: Peroxisome proliferation: Current mechanisms relating to non-genotoxic carcinogenesis. Toxicol Lett 82 3: 673-681,1995
7. Masters C, Crane D: The Peroxisome A Vital Organelle. Cambridge University Press. Cambridge. 1995
8. de Duve C: Microbodies in the living cell. Sci Am 248: 52-62,1983
9. van den Bosch H, Schutgens RBH, Wanders RJA, Tager JM: Biochemistry of peroxisomes. Ann Rev Biochem 61: 157-197,1992
10. Roels F: Peroxisomes. VLB Press, Brussels,1991
11. Moser HW: In: H. Harris, K. Hirschhorn (eds). Peroxisomal Disorders and Advances in Human Oenetics. Vol. 21. Plenum, New York, 1993, pp 1-106
12. Masters C, Holmes R: Peroxisomes, new aspects of cell physiology and biochemistry. Physiol Rev 57: 816-882,1977
13. Keller JM, Cable S, Elbouhtory F, Heusser S, Scotto C, Armbruster L, Ciolek E, Colin S, Schilt J: Peroxisomes through cell differentiation and neoplasia. Biol Cell 77: 77-88,1993
14. Peterson SL, Stevenson PM: Changes in catalase activity and concentration during ovarian development and differentiation. Biochem Biophys Acta 1135: 207-214,1992
15. Van den Branden C, Dacremont G, Hoogh R, Roels F: Inhibition of peroxisomal β-oxidation and brain development in rats. Glia 2: 260-265,1989
16. Lazo O, Singh AK, Singh I: Postnatal development and isolation of peroxisomes from brain. J Neurochem 56: 1343-1353,1991
17. Mangelsdorf DJ, Kliewer SA, Kakizuke A, Umesono K, Evans RM: Retinoid receptors. Recent Prog Horm Res 48: 99-121,1993
18. Beier K, Volkl A, Fahimi HD: The impact of aging on enzyme proteins of rat liver peroxisomes: Quantitative analysis by immunoblotting and immunoelectron microscopy. VirchowsArch B Cell Pathol 63: 139-146,1993
19. Perichon R, Bourre JM: Liver peroxisomal fatty acid oxidizing system during aging in control and clofibrate-treated mice. Biochem Mol Biol Int 37: 475-480,1995
20. Greenstein JP, Jenrette WV, White J: The liver catalase activity of tumour-bearing rats and the effect of extirpation of the tumours. J Natl Cancer Inst 2: 283-291,1941
21. Greenstein JP: Biochemistry of Cancer. Academic Press, New York, 1947, pp 325-330
22. Nishimura ET, Kobara TY, Kaltenbach JP, Wartman WB: Immunological evidence of repressed catalase synthesis in livers of tumour-bearing mice. Arch Biochem Biophys 97: 589-595,1962
23. Rabilloud T, Asselineau D, Miguel C, Calvayrac R, Darmon M, Vuillaume M: Deficiency in catalase activity correlates with the appearance of tumour phenotype in human keratinocytes. Int J Cancer 45: 952-956,1990
24. Kampschmidt RF: Mechanism of liver catalase depression in tumour - bearing animals: A review. Cancer Res 25: 34-45,1964
25. Green S: Receptor mediated mechanisms of peroxisome proliferators. Biochem Pharmacol 43: 393-401,1992
26. Green S, Tugwood JD, Isseman I: The molecular mechanism of peroxisome proliferator action: A model for species differences and mechanistic risk assessment. Toxicol Lett 131 9: 64-65,1992
27. Masters C, Crane D: Recent developments in peroxisome biology. Endeavour 20: 68-73,1996
28. Dreyer C, Krey G, Keller H, Givel F, Helftenbein O, Wahli W: Control of the peroxisomal β oxidation pathway by a novel family of nuclear hormone receptors. Cell 68: 879-887,1992
29. Desvergme B, Wahli W: PPAR: A key nuclear factor in nutrient/gene interactions. In: P. Baeurle (ed). Progress in Oene Expression. Vol. 1. Birkhaüser, Boston, 1994, pp 142-176
30. Kliewer SA, Forman BM, Ong ES, Borgmeyer V. Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359,1994
31. Bojes HK, Thurman RG: Peroxisomal proliferators inhibit acyl CoA synthetase and stimulate protein kinase C in vivo. Toxicol Appl Pharmacol 126: 233-239,1994
32. Wahli W, Braissant O, Desvergne B: Peroxisome proliferator activated receptors: Transcriptional regulators of adipogenesis, lipid metabolism and more. . . Chemistry and Biology 2: 261-266,1995
33. Kvans RM: The steroid and thyroid hormones receptor super family science 240: 889-895,1988
34. Van Poppel G: Carotenoids and cancer: An update with emphasis on human intervention studies. Eur J Cancer 29A: 1335-1344,1993
35. Moon MK, Mehta M: Chemoprevention of mammary cancer by retinoids. Basic Life Sci 52: 213-224,1990
36. Chawla A, Lazar MA: Peroxisome proliferator and retinoid signaling pathways coregulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 91: 1786-1790,1994
37. Stunnenberg HG: Mechanisms of transactivation by retinoic acid receptors. Bioessays 15: 309- 315,1993
38. Sher T,Yi H-F, McBride OW, Gonzalez FJ: CDN A cloning chromosomal mapping and functional characterization of the human peroxisome proliferator activated receptor. Biochemistry 32: 5598-5604,1993
39. Crane DI, Masters CM: Alterations in the integrity of peroxisomal membranes in livers of mice treated with peroxisome proliferators. Mol Cell Biochem 96: 153-161,1990
40. Vineis P, Brandt-Rauf PW: Mechanisms of carcinogenesis: Chemical exposure and molecular changes. Eur J Biochem 29A: 1344-1347,1993
41. Miyashita T, Reed JC: Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299,1995
42. Hunter T: Braking the cycle cell 75: 839-841,1993
43. Rao MS, Yeldandi AV, Subbarao V, Reddy JK: Evidence that ciprofibrate, a potent peroxisome proliferator is a complete carcinogen in the rat. Proc Am Assoc Cancer Res 31: 86,1990
44. Rao MS, Reddy JK: An overview of peroxisome proliferator-induced hepatocarcinogenesis. Knviron Health Perspect 93: 205-209,1991
45. Yokoyama Y, Tsuchida S, Hatayama I, Sato K: Lack of peroxisomal enzyme inducibility in rat hepatic preeoplastic lesions induced by mutagenic carcinogens: Contrasted expression of glutathione S-transferase P form and enoyl CoA hydratase carcinogenesis 14: 393-398,1993
46. Dhaunsi GS, Singh I, Orak JK, Singh AK: Antioxidant enzymes in ciprofibrate-induced oxidative stress. Carcinogenesis 15: 1923-1930,1994
47. Orellana A, Holoigue L, Hidalgo PC, Faundez V, Gonzalez A, Bronfman M: Ciprofibrate, a carcinogenic peroxisome proliferator, increases the phosphorylation of epidermal growth factor receptor in isolated rat hepatocytes. Eur J Biochem 215: 903-906,1993
48. Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxidants and the degenerative diseases of ageing. Proc Natl Acad Sci USA 90: 7915-7922,1993
49. Moody DE, Reddy JK, Lake BG, Popp JA, Reese DH: Peroxisome proliferation and non-genotoxic carcinogenesis commentary on a symposium. Fund Appl Toxicol 16(2): 233-248,1991
50. Clayson DB, Mehta R, Iverson F: Oxidative DNA damage the effects of certain genotoxic and operationally non-genotoxic carcinogens. Mutat Res 317: 25-42,1994
51. Rao MS, Lalwani ND, Watanabe TK, Reddy JK: Inhibitory effects of anitoxidants ethoxyquin and 2(3)-tert-buty-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res 44: 1072-1076,1984
52. Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527-605,1979
53. Janssen YMW, Houten B, Borm PJA, Mossmann BT: Cell and tissue responses to oxidative damage. Lab Invest 69: 261-271,1993
54. Sun Y: Free radicals, antioxidant enzymens and carcinogenesis. Free Rad Biol Med 8: 583-599,1990
55. Takagi A, Sai K, Umemura T, Hasegawa R, Kurokawa Y: Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyquanosine formation in liver DNA of rats following long term exposure to three peroxisome proliferators. Cancer Lett 53: 33-38,1990
56. Cattley RC, Glover SK: Hlevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to carcinogenesis and nuclear localisation carcinogenesis 14: 2495-2499,1993
57. Ames BN, Gold LS: Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 249: 970-971,1990
58. Grisham JW, Kaufman WK, Kaufman DG: The cell cycle and carcinogenesis. Surv Synth Pathol Res 1: 49-66,1983
59. Lehninger AL, Nelson DL, Cox MM: Principles of Biochemistry, 2nd edn. Worth Publishers, New York,1992
60. Hegi ME, Fox TR, Belinsky SA, Devereux TR, Anderson MA: Analysis of activated protooncogenes in B6C3F1 mouse liver tumours induced by ciprofibrate, a potent peroxisome proliferator. Carcinogenesis 14: 145-149,1993
61. Hamilton GA: Oxalyl thiolesters, novel intermediates in biological systems. In: V.T. D'Souza, T. Feder (eds).The Bioorganic Chemistry of Enzymatic Analysis: An Homage to Myron L. Bender, CRC Press, Ann Arbor, 1991, pp 79-89
62. Hamilton GA: Peroxisomal oxidases and suggestions for the mechanism of action of insulin and other hormones. Adv Enzymol 57: 85-178,1985
63. Masters C: Cellular signalling: The role of the peroxisome Cell. Signalling 8: 197-208,1996
64. Borek C: ω-3 Fatty acids as an anticarcinogens: Cellular and molecular studies. In: C. Galli, A.P. Simopoulos, E. Tremoli (eds). Effects of Fatty Acids and Lipids in Health and Disease. Vol. 76, Karger, Basel, 1994, pp 66-69
65. Masters C: Omega-3 fatty acids and the peroxisome. Mol Cell Biochem 165: 83-93,1996
66. Lake BG: Mechanisms of hepatocarcinogenility of peroxisome proliferating drugs and chemicals. Ann Rev Pharmacol Toxicol 35: 483-507,1995
67. Bayly AL, Roberts RA, Dive C: Suppression of liver cell apoptosis in vitro by the nongenotoxic hepatocarcinogen and peroxisome proliferator nafenopin. Cell Biol 125: 197-203,1994
68. Bayly AC, French NJ, Dive C, Roberts RA: Non genotoxic hepatocarcinogenesis in vitro: The FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. J Cell Sci 104: 307-315,1993
69. Kashiwagi A: Peroxisomal enzyme activity changes in the tail of Anuran tadpoles during metamorphosis. Comp Biochem Physiol B Biochem Mol Biol III: 483-489,1995
70. Claria J, Serhan HN: Aspirin triggers previously underscribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92: 9475-9482,1995
71. Masters C: On the role of the peroxisome in the metabolism of drugs and xenobiotics. Biochem Pharmacol (in press)